Post-translational modifications (PTMs) on tau have long been recognized as affecting
protein function and contributing to neurodegeneration. The explosion of information on …

Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established
biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain …

Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a
global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both …

α-synuclein (α-syn) is a protein associated with the pathogenesis of Parkinson's disease
(PD), the second most common neurodegeneration disease with no effective treatment …

Alzheimer's disease (AD) is characterized by an imbalance between production and
clearance of amyloid-β (Aβ) species. Aβ peptides can transform structurally from monomers …

Alpha-synuclein is a protein implicated in Parkinson's disease and thought to be one of the
main pathological drivers in the disease, although it remains unclear how this protein elicits …

Small molecule drug discovery has been propelled by the continual development of novel
scientific methodologies to occasion therapeutic advances. Although established …

Protein instability caused by exposure to external additives or severe stress may result in
different diseases. Of these diseases, many are triggered by protein misfolding and …

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
affecting upper and lower motor neurons, with death resulting mainly from respiratory failure …